TrialJCO precision oncology2024

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.

Monica F Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.